ABVC logo

ABVC BIOPHARMA INC

ABVCNASDAQ
πŸ† #4496 by market capUS Equity
$0.86β–Ό $0.02 (βˆ’2.82%)
Market closed Β· at close
πŸ””
Track ABVC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.8%
7dβ–Ό 11.3%
14dβ–Ό 11.8%
30dβ–Ό 9.0%
ytdβ–Ό 59.4%
1yβ–Ό 68.4%
🏦Market Cap
$23M
Small Cap
πŸ“ˆRevenue Growth (YoY)
103.4%
High Growth
πŸ“ŠGross Margin
0.3%
Thin
πŸ’΅FCF Margin
21.3%
Strong
βš–οΈP/S Ratio
29.3x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.86 – $0.89
52-Week Range
$0.71 – $2.96
Volume (shares)
676
Avg Volume (shares)
β€”
Shares Outstanding
26.7M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
29.3x
EPS (TTM)
$-0.32
Dividend Yield
β€”
Dilution (1yr)
+74.6%
ABVC logo

ABVC BIOPHARMA INC

ABVC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.9%β–Ό βˆ’201.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$7Mβ–² +52.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$3Mβ–² +65.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.3Mβ–² +74.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$3Mβ–Ό βˆ’$451K YoY
StockOtter Β· stockotter.space

About ABVC BIOPHARMA INC

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Oct 2023

Latest News & Updates

News unavailable.